Signaling Receptors for TGF-β Family Members.

Transforming growth factor β (TGF-β) family members signal via heterotetrameric complexes of type I and type II dual specificity kinase receptors. The activation and stability of the receptors are controlled by posttranslational modifications, such as phosphorylation, ubiquitylation, sumoylation, and neddylation, as well as by interaction with other proteins at the cell surface and in the cytoplasm. Activation of TGF-β receptors induces signaling via formation of Smad complexes that are translocated to the nucleus where they act as transcription factors, as well as via non-Smad pathways, including the Erk1/2, JNK and p38 MAP kinase pathways, and the Src tyrosine kinase, phosphatidylinositol 3'-kinase, and Rho GTPases.

[1]  C. Heldin,et al.  Signals and Receptors. , 2016, Cold Spring Harbor perspectives in biology.

[2]  G. Blobe,et al.  TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling , 2015, Molecular biology of the cell.

[3]  Lily Huang,et al.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A , 2015, Science Translational Medicine.

[4]  C. Heldin,et al.  CIN85 modulates TGFβ signaling by promoting the presentation of TGFβ receptors on the cell surface , 2015, The Journal of cell biology.

[5]  H. Gerhardt,et al.  Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch , 2015, Nature Communications.

[6]  T. Nheu,et al.  SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor* , 2015, The Journal of Biological Chemistry.

[7]  X. Wang,et al.  Regulatory MiR‐148a‐ACVR1/BMP circuit defines a cancer stem cell‐like aggressive subtype of hepatocellular carcinoma , 2015, Hepatology.

[8]  J. Baselga,et al.  Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer , 2014, Investigational New Drugs.

[9]  J. Baselga,et al.  Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study , 2014, Cardiovascular Toxicology.

[10]  J. Baselga,et al.  First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma , 2014, Clinical Cancer Research.

[11]  G. Sapkota,et al.  The emerging roles of deubiquitylating enzymes (DUBs) in the TGFβ and BMP pathways , 2014, Cellular signalling.

[12]  G. Blobe,et al.  Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion , 2014, Molecular biology of the cell.

[13]  Zhiguo Lin,et al.  miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. , 2014, Carcinogenesis.

[14]  Xiwu Chen,et al.  Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling. , 2014, The Journal of clinical investigation.

[15]  G. Blobe,et al.  Role of TGF-β receptor III localization in polarity and breast cancer progression , 2014, Molecular biology of the cell.

[16]  Jodie L Babitt,et al.  MicroRNA-130a Is Up-regulated in Mouse Liver by Iron Deficiency and Targets the Bone Morphogenetic Protein (BMP) Receptor ALK2 to Attenuate BMP Signaling and Hepcidin Transcription* , 2014, The Journal of Biological Chemistry.

[17]  C. Heldin,et al.  Platelet-derived Growth Factor β-Receptor, Transforming Growth Factor β Type I Receptor, and CD44 Protein Modulate Each Other's Signaling and Stability* , 2014, The Journal of Biological Chemistry.

[18]  G. Sapkota,et al.  USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling , 2014, Open Biology.

[19]  Stephen Yip,et al.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.

[20]  Michael Brudno,et al.  Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations , 2014, Nature Genetics.

[21]  K. Zen,et al.  miR‐17 regulates the proliferation and differentiation of the neural precursor cells during mouse corticogenesis , 2014, The FEBS journal.

[22]  C. Heldin,et al.  TRAF6 Stimulates the Tumor-Promoting Effects of TGFβ Type I Receptor Through Polyubiquitination and Activation of Presenilin 1 , 2014, Science Signaling.

[23]  Xiaochun Yu,et al.  Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17–92 cluster in carotid artery restenosis , 2013, Molecular and Cellular Biochemistry.

[24]  K. Zen,et al.  Role of miR-17 Family in the Negative Feedback Loop of Bone Morphogenetic Protein Signaling in Neuron , 2013, PloS one.

[25]  F. Tsai,et al.  BMPR1B Up-Regulation via a miRNA Binding Site Variation Defines Endometriosis Susceptibility and CA125 Levels , 2013, PloS one.

[26]  G. Blobe,et al.  Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. , 2013, The Journal of clinical investigation.

[27]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[28]  Xiao-ming Meng,et al.  Dragon (Repulsive Guidance Molecule RGMb) Inhibits E-cadherin Expression and Induces Apoptosis in Renal Tubular Epithelial Cells* , 2013, The Journal of Biological Chemistry.

[29]  Craig Mickanin,et al.  TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. , 2013, Molecular cell.

[30]  D. Bernstein,et al.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. , 2013, The Journal of clinical investigation.

[31]  S. Murphy,et al.  Retromer maintains basolateral distribution of the type II TGF-β receptor via the recycling endosome , 2013, Molecular biology of the cell.

[32]  A. Burlingame,et al.  Arginine Methylation Initiates BMP-Induced Smad Signaling. , 2013, Molecular cell.

[33]  R. Chang,et al.  MicroRNA‐140‐5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma , 2013, Hepatology.

[34]  L. Wakefield,et al.  Beyond TGFβ: roles of other TGFβ superfamily members in cancer , 2013, Nature Reviews Cancer.

[35]  Y. Mishina,et al.  Constitutively Active ALK2 Receptor Mutants Require Type II Receptor Cooperation , 2013, Molecular and Cellular Biology.

[36]  V. Kaartinen,et al.  TGF-β-activated Kinase 1 (Tak1) Mediates Agonist-induced Smad Activation and Linker Region Phosphorylation in Embryonic Craniofacial Neural Crest-derived Cells* , 2013, The Journal of Biological Chemistry.

[37]  S. Chien,et al.  BMP receptor‐integrin interaction mediates responses of vascular endothelial Smad1/5 and proliferation to disturbed flow , 2013, Journal of thrombosis and haemostasis : JTH.

[38]  Yue Jiang,et al.  MicroRNA-181a Suppresses Mouse Granulosa Cell Proliferation by Targeting Activin Receptor IIA , 2013, PloS one.

[39]  Jun Du,et al.  c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. , 2013, Molecular cell.

[40]  R. Ravazzolo,et al.  The Role of the 3′UTR Region in the Regulation of the ACVR1/Alk-2 Gene Expression , 2012, PloS one.

[41]  D. Brazil,et al.  CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGF&bgr; type II receptor with implications for nephropathic cell phenotypes , 2012, Journal of Cell Science.

[42]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[43]  J. Qian,et al.  MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11 , 2012, Oncotarget.

[44]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[45]  Yue Jiang,et al.  MicroRNA‐145 suppresses mouse granulosa cell proliferation by targeting activin receptor IB , 2012, FEBS letters.

[46]  R. Jain,et al.  TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma , 2012, Proceedings of the National Academy of Sciences.

[47]  J. Massagué TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[48]  B. Davis-Dusenbery,et al.  Inhibition of MicroRNA-302 (miR-302) by Bone Morphogenetic Protein 4 (BMP4) Facilitates the BMP Signaling Pathway* , 2012, The Journal of Biological Chemistry.

[49]  I. Keklikoglou,et al.  MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways , 2012, Oncogene.

[50]  Stefan Knapp,et al.  Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva , 2012, The Journal of Biological Chemistry.

[51]  Wei-Guo Zhu,et al.  MiR-135a functions as a selective killer of malignant glioma , 2012, Oncogene.

[52]  Sha Huang,et al.  MicroRNA‐100 regulates osteogenic differentiation of human adipose‐derived mesenchymal stem cells by targeting BMPR2 , 2012, FEBS letters.

[53]  Y. Henis,et al.  Oligomeric interactions of TGF‐β and BMP receptors , 2012, FEBS letters.

[54]  Jeff Porter,et al.  USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor , 2012, Nature Cell Biology.

[55]  G. Sapkota,et al.  USP11 augments TGFβ signalling by deubiquitylating ALK5 , 2012, Open Biology.

[56]  K. M. Mulder,et al.  The TGFβ Receptor-interacting Protein km23-1/DYNLRB1 Plays an Adaptor Role in TGFβ1 Autoinduction via Its Association with Ras* , 2012, The Journal of Biological Chemistry.

[57]  I. Leuschner,et al.  miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. , 2012, Carcinogenesis.

[58]  P. ten Dijke,et al.  Key role for ubiquitin protein modification in TGFβ signal transduction , 2012, Upsala journal of medical sciences.

[59]  M. Goumans,et al.  Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting* , 2012, The Journal of Biological Chemistry.

[60]  Albert-László Barabási,et al.  MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension: Results of a Network Bioinformatics Approach , 2012, Circulation.

[61]  C. Heldin,et al.  Transcriptional Induction of Salt-inducible Kinase 1 by Transforming Growth Factor β Leads to Negative Regulation of Type I Receptor Signaling in Cooperation with the Smurf2 Ubiquitin Ligase* , 2012, The Journal of Biological Chemistry.

[62]  J. Baselga,et al.  USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma , 2012, Nature Medicine.

[63]  C. Bianco,et al.  An evolving web of signaling networks regulated by Cripto-1 , 2012, Growth factors.

[64]  A. Philip,et al.  CD109‐mediated degradation of TGF‐β receptors and inhibition of TGF‐β responses involve regulation of SMAD7 and Smurf2 localization and function , 2012, Journal of cellular biochemistry.

[65]  Leonardo Morsut,et al.  USP15 is a deubiquitylating enzyme for receptor-activated SMADs , 2011, Nature Cell Biology.

[66]  M. Scheideler,et al.  MicroRNA-30c promotes human adipocyte differentiation and co-represses PAI-1 and ALK2 , 2011, RNA biology.

[67]  P. Wang,et al.  TSC-22 Promotes Transforming Growth Factor β-Mediated Cardiac Myofibroblast Differentiation by Antagonizing Smad7 Activity , 2011, Molecular and Cellular Biology.

[68]  A. Ristimäki,et al.  BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. , 2011, Gastroenterology.

[69]  Wei Zhang,et al.  A miR-125b binding site polymorphism in bone morphogenetic protein membrane receptor type IB gene and prostate cancer risk in China , 2011, Molecular Biology Reports.

[70]  Robert L. Judson,et al.  Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells , 2011, Nature Biotechnology.

[71]  C. Heldin,et al.  TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer , 2011, Nature communications.

[72]  A. Philip,et al.  The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors. , 2011, Biochimica et biophysica acta.

[73]  A. Hinck,et al.  TGF‐β signalling is mediated by two autonomously functioning TβRI:TβRII pairs , 2011, The EMBO journal.

[74]  Y. Glinka,et al.  Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. , 2011, Carcinogenesis.

[75]  G. Fu,et al.  MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance , 2011, Journal of Cell Science.

[76]  Wei Li,et al.  TβRI/Alk5-independent TβRII signaling to ERK1/2 in human skin cells according to distinct levels of TβRII expression , 2011, Journal of Cell Science.

[77]  P. Robinson,et al.  Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity , 2010, Journal of Cell Science.

[78]  Francis Impens,et al.  The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. , 2010, Molecular cell.

[79]  P. Howe,et al.  Type II Transforming Growth Factor-β Receptor Recycling Is Dependent upon the Clathrin Adaptor Protein Dab2 , 2010, Molecular Biology of the Cell.

[80]  A. Atfi,et al.  The oncoprotein c-ski functions as a direct antagonist of the transforming growth factor-{beta} type I receptor. , 2010, Cancer research.

[81]  P. Lehner,et al.  Identification of a Lysosomal Pathway Regulating Degradation of the Bone Morphogenetic Protein Receptor Type II , 2010, The Journal of Biological Chemistry.

[82]  D. Mukhopadhyay,et al.  Neuropilin-1 Mediates Divergent R-Smad Signaling and the Myofibroblast Phenotype* , 2010, The Journal of Biological Chemistry.

[83]  K. Miyazono,et al.  Smad7 Inhibits Transforming Growth Factor-β Family Type I Receptors through Two Distinct Modes of Interaction* , 2010, The Journal of Biological Chemistry.

[84]  A. Hinck,et al.  Ternary Complex of Transforming Growth Factor-β1 Reveals Isoform-specific Ligand Recognition and Receptor Recruitment in the Superfamily* , 2010, The Journal of Biological Chemistry.

[85]  Gerard C Blobe,et al.  ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. , 2010, Carcinogenesis.

[86]  Zhen-ping Zhu,et al.  Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells , 2010, Clinical Cancer Research.

[87]  T. Clemens,et al.  TGF-β type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling , 2010, Nature Cell Biology.

[88]  J. Lieberman,et al.  Molecular basis for antagonism between PDGF and the TGFβ family of signalling pathways by control of miR‐24 expression , 2010, The EMBO journal.

[89]  M. Goumans,et al.  Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis , 2010, The Journal of experimental medicine.

[90]  A. Hinck,et al.  Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. , 2009, Biochemistry.

[91]  M. Goumans,et al.  ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP‐induced osteoblast differentiation and bone formation , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[92]  C. Heldin,et al.  The regulation of TGFβ signal transduction , 2009, Development.

[93]  G. Blobe,et al.  The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. , 2009, Molecular biology of the cell.

[94]  David Smith,et al.  A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. , 2009, Cancer research.

[95]  Qianqian Wang,et al.  Single-molecule imaging reveals transforming growth factor-β-induced type II receptor dimerization , 2009, Proceedings of the National Academy of Sciences.

[96]  F. Chen,et al.  Human BAMBI Cooperates with Smad7 to Inhibit Transforming Growth Factor-β Signaling* , 2009, The Journal of Biological Chemistry.

[97]  R. Derynck,et al.  Essential role of TGF-beta signaling in glucose-induced cell hypertrophy. , 2009, Developmental cell.

[98]  Samy Lamouille,et al.  TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. , 2009, Molecular cell.

[99]  Sheng-Cai Lin,et al.  Rock2 controls TGFβ signaling and inhibits mesoderm induction in zebrafish embryos , 2009, Journal of Cell Science.

[100]  Min Xie,et al.  TAK1 is an essential regulator of BMP signalling in cartilage , 2009, The EMBO journal.

[101]  Maozhen Tian,et al.  X-linked Inhibitor of Apoptosis Protein and Its E3 Ligase Activity Promote Transforming Growth Factor-β-mediated Nuclear Factor-κB Activation during Breast Cancer Progression* , 2009, The Journal of Biological Chemistry.

[102]  Y. Henis,et al.  Novel crosstalk to BMP signalling: cGMP‐dependent kinase I modulates BMP receptor and Smad activity , 2009, The EMBO journal.

[103]  R. Speich,et al.  Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 Pathway , 2009, Circulation research.

[104]  G. Blobe,et al.  The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42 , 2009, Proceedings of the National Academy of Sciences.

[105]  Xin-Hua Feng,et al.  Transforming Growth Factor β Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors* , 2009, Journal of Biological Chemistry.

[106]  Y. Henis,et al.  Different Domains Regulate Homomeric and Heteromeric Complex Formation among Type I and Type II Transforming Growth Factor-β Receptors* , 2009, Journal of Biological Chemistry.

[107]  S. Mundlos,et al.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1 , 2009, Human mutation.

[108]  C. Ouzounis,et al.  Emergence, development and diversification of the TGF-β signalling pathway within the animal kingdom , 2009, BMC Evolutionary Biology.

[109]  R. Derynck,et al.  TGFβ‐stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro‐migratory TGFβ switch , 2009, The EMBO journal.

[110]  H. You,et al.  Endocytosis of the Type III Transforming Growth Factor-β (TGF-β) Receptor through the Clathrin-independent/Lipid Raft Pathway Regulates TGF-β Signaling and Receptor Down-regulation* , 2008, Journal of Biological Chemistry.

[111]  G. Blobe,et al.  Endoglin Promotes Transforming Growth Factor β-mediated Smad 1/5/8 Signaling and Inhibits Endothelial Cell Migration through Its Association with GIPC* , 2008, Journal of Biological Chemistry.

[112]  C. Heldin,et al.  The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner , 2008, Nature Cell Biology.

[113]  M. Yamashita,et al.  TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. , 2008, Molecular cell.

[114]  M. Howell,et al.  Two highly related regulatory subunits of PP2A exert opposite effects on TGF-β/Activin/Nodal signalling , 2008, Development.

[115]  C. Heldin,et al.  Jcb: Report , 2022 .

[116]  Mary E. Choi,et al.  BAT3 Interacts with Transforming Growth Factor-β (TGF-β) Receptors and Enhances TGF-β1-induced Type I Collagen Expression in Mesangial Cells* , 2008, Journal of Biological Chemistry.

[117]  Xin-Hua Feng,et al.  Critical regulation of TGFβ signaling by Hsp90 , 2008, Proceedings of the National Academy of Sciences.

[118]  R. Derynck,et al.  The type I TGF-β receptor is covalently modified and regulated by sumoylation , 2008, Nature Cell Biology.

[119]  M. Corada,et al.  VE‐cadherin is a critical endothelial regulator of TGF‐β signalling , 2008, The EMBO journal.

[120]  G. Blobe,et al.  Bone Morphogenetic Proteins Signal through the Transforming Growth Factor-β Type III Receptor* , 2008, Journal of Biological Chemistry.

[121]  P. Dijke,et al.  L- and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts , 2008, Journal of Cell Science.

[122]  Joachim Nickel,et al.  Structure Analysis of Bone Morphogenetic Protein-2 Type I Receptor Complexes Reveals a Mechanism of Receptor Inactivation in Juvenile Polyposis Syndrome* , 2008, Journal of Biological Chemistry.

[123]  William P Schiemann,et al.  Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. , 2008, Carcinogenesis.

[124]  L. Myeroff,et al.  Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor β resistant cells , 2008, Genes, chromosomes & cancer.

[125]  A. Hinck,et al.  Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. , 2008, Molecular cell.

[126]  V. Kaartinen,et al.  ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. , 2008, Blood.

[127]  Huiling Xue,et al.  MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. , 2008, Blood.

[128]  J. Massagué,et al.  Genome-wide Impact of the BRG1 SWI/SNF Chromatin Remodeler on the Transforming Growth Factor β Transcriptional Program* , 2008, Journal of Biological Chemistry.

[129]  M. Kwak,et al.  TrkC binds to the type II TGF-β receptor to suppress TGF-β signaling , 2007, Oncogene.

[130]  H. You,et al.  The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. , 2007, Carcinogenesis.

[131]  P. Dijke,et al.  Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.

[132]  Seong-Jin Kim,et al.  TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. , 2007, Cancer research.

[133]  Y. Henis,et al.  A unique element in the cytoplasmic tail of the type II transforming growth factor-beta receptor controls basolateral delivery. , 2007, Molecular biology of the cell.

[134]  Uyen Tran,et al.  MicroRNA control of Nodal signalling , 2007, Nature.

[135]  Jing Qing,et al.  TGF‐β activates Erk MAP kinase signalling through direct phosphorylation of ShcA , 2007 .

[136]  F. Colland,et al.  The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor , 2007, The Journal of cell biology.

[137]  K. Miyazono,et al.  Selective Inhibitory Effects of Smad6 on Bone Morphogenetic Protein Type I Receptors* , 2007, Journal of Biological Chemistry.

[138]  K. M. Mulder,et al.  Requirement for the Dynein Light Chain km23-1 in a Smad2-dependent Transforming Growth Factor-β Signaling Pathway* , 2007, Journal of Biological Chemistry.

[139]  H. Beppu,et al.  Repulsive Guidance Molecule RGMa Alters Utilization of Bone Morphogenetic Protein (BMP) Type II Receptors by BMP2 and BMP4* , 2007, Journal of Biological Chemistry.

[140]  A. Hata,et al.  A Novel Regulatory Mechanism of the Bone Morphogenetic Protein (BMP) Signaling Pathway Involving the Carboxyl-Terminal Tail Domain of BMP Type II Receptor , 2007, Molecular and Cellular Biology.

[141]  A. Gressner,et al.  Endoglin Differentially Modulates Antagonistic Transforming Growth Factor-β1 and BMP-7 Signaling* , 2007, Journal of Biological Chemistry.

[142]  Hyun-A Seong,et al.  NM23-H1 Tumor Suppressor Physically Interacts with Serine-Threonine Kinase Receptor-associated Protein, a Transforming Growth Factor-β (TGF-β) Receptor-interacting Protein, and Negatively Regulates TGF-β Signaling* , 2007, Journal of Biological Chemistry.

[143]  W. Schiemann,et al.  Src phosphorylates Tyr284 in tgf-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion , 2007 .

[144]  Xu Cao,et al.  Endofin acts as a Smad anchor for receptor activation in BMP signaling , 2007, Journal of Cell Science.

[145]  L. David,et al.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.

[146]  J. Coselli,et al.  Severe aortic and arterial aneurysms associated with a TGFBR2 mutation , 2007, Nature Clinical Practice Cardiovascular Medicine.

[147]  Juswinder Singh,et al.  A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection , 2007 .

[148]  A. Meng,et al.  The evolutionally conserved activity of Dapper2 in antagonizing TGF‐ß signaling , 2007 .

[149]  B. Moeller,et al.  The type III TGF-β receptor suppresses breast cancer progression , 2007 .

[150]  K. Miyazono,et al.  Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line , 2007, Cancer science.

[151]  M. Asashima,et al.  Dullard promotes degradation and dephosphorylation of BMP receptors and is required for neural induction. , 2006, Developmental cell.

[152]  A. Heagerty,et al.  Identification of Tctex2β, a Novel Dynein Light Chain Family Member That Interacts with Different Transforming Growth Factor-β Receptors* , 2006, Journal of Biological Chemistry.

[153]  R. Akhurst,et al.  TGF beta inhibition for cancer therapy. , 2006, Current cancer drug targets.

[154]  W. Vale,et al.  Cripto Binds Transforming Growth Factor β (TGF-β) and Inhibits TGF-β Signaling , 2006, Molecular and Cellular Biology.

[155]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[156]  G. Cesareni,et al.  Conjugation to Nedd8 Instigates Ubiquitylation and Down-regulation of Activated Receptor Tyrosine Kinases* , 2006, Journal of Biological Chemistry.

[157]  K. Rommel,et al.  TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys‐Dietz syndrome , 2006, Human mutation.

[158]  William P Schiemann,et al.  β3 Integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells , 2006, Breast Cancer Research.

[159]  M. Reiss,et al.  Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo , 2006, Clinical Cancer Research.

[160]  Xiu-fen Lei,et al.  Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. , 2006, Cancer research.

[161]  P. Lepage,et al.  Identification of CD109 as part of the TGF‐β receptor system in human keratinocytes , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[162]  K. Lewis,et al.  Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. , 2006, The Journal of biological chemistry.

[163]  Raymond T Chung,et al.  Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression , 2006, Nature Genetics.

[164]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[165]  Fumiko Itoh,et al.  Smad7 and protein phosphatase 1α are critical determinants in the duration of TGF-β/ALK1 signaling in endothelial cells , 2006, BMC Cell Biology.

[166]  Kyong-Tai Kim,et al.  Regulation of Transforming Growth Factor-β Signaling and PDK1 Kinase Activity by Physical Interaction between PDK1 and Serine-Threonine Kinase Receptor-associated Protein* , 2005, Journal of Biological Chemistry.

[167]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[168]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[169]  P. Sorensen,et al.  The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-β signaling by inactivating the TGF-β type II receptor , 2005 .

[170]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[171]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[172]  S. Shete,et al.  Mutations in Transforming Growth Factor-&bgr; Receptor Type II Cause Familial Thoracic Aortic Aneurysms and Dissections , 2005, Circulation.

[173]  J. Knowles,et al.  Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. , 2005, American journal of respiratory cell and molecular biology.

[174]  A. de la Chapelle,et al.  TGFBR1*6A may contribute to hereditary colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  A. Brivanlou,et al.  DRAGON, a Bone Morphogenetic Protein Co-receptor* , 2005, Journal of Biological Chemistry.

[176]  Jae Youn Yi,et al.  Type I Transforming Growth Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase* , 2005, Journal of Biological Chemistry.

[177]  Natasa Przulj,et al.  High-Throughput Mapping of a Dynamic Signaling Network in Mammalian Cells , 2005, Science.

[178]  Yue Zhang,et al.  Regulation of the Polarity Protein Par6 by TGFß Receptors Controls Epithelial Cell Plasticity , 2005, Science.

[179]  Ning Chen,et al.  Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia , 2005, Human mutation.

[180]  M. Manns,et al.  Hepatic manifestation is associated with ALK1 in hereditary hemorrhagic telangiectasia: Identification of five novel ALK1 and one novel ENG mutations , 2005, Human mutation.

[181]  J. Wrana,et al.  Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP‐dependent dendritogenesis , 2004, The EMBO journal.

[182]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[183]  Stefan Mundlos,et al.  Modulation of GDF5/BRI‐b signalling through interaction with the tyrosine kinase receptor Ror2 , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[184]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.

[185]  M. Goumans,et al.  Endoglin promotes endothelial cell proliferation and TGF‐β/ALK1 signal transduction , 2004, The EMBO journal.

[186]  J. Dennis,et al.  Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis , 2004, Science.

[187]  R. Hollingsworth,et al.  CD44 modulates Smad1 activation in the BMP-7 signaling pathway , 2004, The Journal of cell biology.

[188]  Ossama Tawfik,et al.  BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt–β-catenin signaling , 2004, Nature Genetics.

[189]  P. Pandolfi,et al.  Cytoplasmic PML function in TGF-β signalling , 2004, Nature.

[190]  R. Pagano,et al.  Ligand-dependent and -independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11. , 2004, Molecular biology of the cell.

[191]  W. Sebald,et al.  Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction , 2004, Biological chemistry.

[192]  T. Akiyama,et al.  Transcriptional regulation of the TGF-β pseudoreceptor BAMBI by TGF-β signaling , 2004 .

[193]  Yusuke Nakamura,et al.  Heterozygous TGFBR2 mutations in Marfan syndrome , 2004, Nature Genetics.

[194]  H T Lynch,et al.  The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations , 2004, Journal of Medical Genetics.

[195]  P. Thompson,et al.  αvβ3 Integrin Interacts with the Transforming Growth Factor β (TGFβ) Type II Receptor to Potentiate the Proliferative Effects of TGFβ1 in Living Human Lung Fibroblasts* , 2004, Journal of Biological Chemistry.

[196]  C. Heldin,et al.  Id2 and Id3 Define the Potency of Cell Proliferation and Differentiation Responses to Transforming Growth Factor β and Bone Morphogenetic Protein , 2004, Molecular and Cellular Biology.

[197]  R. Coffey,et al.  Differential trafficking of transforming growth factor-beta receptors and ligand in polarized epithelial cells. , 2004, Molecular biology of the cell.

[198]  K. Miyazono,et al.  Endogenous TGF‐β signaling suppresses maturation of osteoblastic mesenchymal cells , 2004, The EMBO journal.

[199]  K. Luo Ski and SnoN: negative regulators of TGF-β signaling , 2004 .

[200]  K. Mockaitis,et al.  Arabidopsis kinome: after the casting , 2004, Functional & Integrative Genomics.

[201]  Xu Cao,et al.  GADD34–PP1c recruited by Smad7 dephosphorylates TGFβ type I receptor , 2004, The Journal of cell biology.

[202]  Jonas Larsson,et al.  Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. , 2003, Molecular cell.

[203]  E. Stanley,et al.  Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1 , 2003, The Journal of cell biology.

[204]  Xiao-Fan Wang,et al.  ß-Arrestin 2 Mediates Endocytosis of Type III TGF-ß Receptor and Down-Regulation of Its Signaling , 2003, Science.

[205]  Dean Y. Li,et al.  Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. , 2003, Developmental biology.

[206]  K. Loveland,et al.  Expression of Bambi is widespread in juvenile and adult rat tissues and is regulated in male germ cells. , 2003, Endocrinology.

[207]  R. Weinberg,et al.  Heart and Liver Defects and Reduced Transforming Growth Factor β2 Sensitivity in Transforming Growth Factor β Type III Receptor-Deficient Embryos , 2003, Molecular and Cellular Biology.

[208]  Jeffrey L. Wrana,et al.  Distinct endocytic pathways regulate TGF-β receptor signalling and turnover , 2003, Nature Cell Biology.

[209]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[210]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[211]  K. M. Mulder,et al.  A novel transforming growth factor-beta receptor-interacting protein that is also a light chain of the motor protein dynein. , 2002, Molecular biology of the cell.

[212]  L. Bourguignon,et al.  Hyaluronan Promotes Signaling Interaction between CD44 and the Transforming Growth Factor β Receptor I in Metastatic Breast Tumor Cells* , 2002, The Journal of Biological Chemistry.

[213]  A. Chawla,et al.  TGFβ receptor internalization into EEA1-enriched early endosomes , 2002, The Journal of Cell Biology.

[214]  T. Sanchez-Elsner,et al.  Extracellular and Cytoplasmic Domains of Endoglin Interact with the Transforming Growth Factor-β Receptors I and II* , 2002, The Journal of Biological Chemistry.

[215]  F. Lallemand,et al.  Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-β/Smad signaling , 2002, Oncogene.

[216]  J. Doré,et al.  Internalization-Dependent and -Independent Requirements for Transforming Growth Factor β Receptor Signaling via the Smad Pathway , 2002, Molecular and Cellular Biology.

[217]  M. Shen,et al.  Dual Roles of Cripto as a Ligand and Coreceptor in the Nodal Signaling Pathway , 2002, Molecular and Cellular Biology.

[218]  M. Lin,et al.  Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. , 2002, Blood.

[219]  Shashank Deep,et al.  Crystal structure of the human TβR2 ectodomain–TGF-β3 complex , 2002, Nature Structural Biology.

[220]  Anja Nohe,et al.  The Mode of Bone Morphogenetic Protein (BMP) Receptor Oligomerization Determines Different BMP-2 Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[221]  M. Reiss,et al.  Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. , 2002, The Journal of biological chemistry.

[222]  M. Reiss,et al.  Novel inactivating mutations of transforming growth factor‐β type I receptor gene in head‐and‐neck cancer metastases , 2001, International journal of cancer.

[223]  J Kuriyan,et al.  The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. , 2001, Molecular cell.

[224]  Xiang-Xi Xu,et al.  The adaptor molecule Disabled‐2 links the transforming growth factor β receptors to the Smad pathway , 2001, The EMBO journal.

[225]  Victor E. Velculescu,et al.  Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis , 2001, Nature Genetics.

[226]  Tomoki Chiba,et al.  Smurf1 Interacts with Transforming Growth Factor-β Type I Receptor through Smad7 and Induces Receptor Degradation* , 2001, The Journal of Biological Chemistry.

[227]  M. Bitzer,et al.  Caveolin-1 Regulates Transforming Growth Factor (TGF)-β/SMAD Signaling through an Interaction with the TGF-β Type I Receptor* , 2001, The Journal of Biological Chemistry.

[228]  R. Dildrop,et al.  Bambi is coexpressed with Bmp-4 during mouse embryogenesis , 2001, Mechanisms of Development.

[229]  P. Corris,et al.  Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein tùype II receptor. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[230]  A. Balmain,et al.  TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G1 arrest , 2000 .

[231]  J. Wrana,et al.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. , 2000, Molecular cell.

[232]  A. Roberts,et al.  Zebrafish nma is involved in TGFβ family signaling , 2000, Genesis.

[233]  T. Kirsch,et al.  Crystal structure of the BMP-2–BRIA ectodomain complex , 2000, Nature Structural Biology.

[234]  Harold L. Moses,et al.  STRAP and Smad7 Synergize in the Inhibition of Transforming Growth Factor β Signaling , 2000, Molecular and Cellular Biology.

[235]  K. Lewis,et al.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling , 2000, Nature.

[236]  K. Miyazono,et al.  Smad6 Is a Smad1/5-induced Smad Inhibitor , 2000, The Journal of Biological Chemistry.

[237]  A. Zargar,et al.  Fibrodysplasia ossificans progressiva. , 1999, Annals of Saudi medicine.

[238]  C. Niehrs,et al.  Silencing of TGF-β signalling by the pseudoreceptor BAMBI , 1999, Nature.

[239]  Morgan Huse,et al.  Crystal Structure of the Cytoplasmic Domain of the Type I TGF β Receptor in Complex with FKBP12 , 1999, Cell.

[240]  J. Wrana,et al.  Endoglin Is an Accessory Protein That Interacts with the Signaling Receptor Complex of Multiple Members of the Transforming Growth Factor-β Superfamily* , 1999, The Journal of Biological Chemistry.

[241]  Harold L. Moses,et al.  Identification of STRAP, a Novel WD Domain Protein in Transforming Growth Factor-β Signaling* , 1998, The Journal of Biological Chemistry.

[242]  Liliana Attisano,et al.  SARA, a FYVE Domain Protein that Recruits Smad2 to the TGFβ Receptor , 1998, Cell.

[243]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.

[244]  R. Derynck,et al.  Physical and Functional Interactions between Type I Transforming Growth Factor β Receptors and Bα, a WD-40 Repeat Subunit of Phosphatase 2A , 1998, Molecular and Cellular Biology.

[245]  R. Frey,et al.  Transforming growth factor β signaling through Smad1 in human breast cancer cells , 1998 .

[246]  L. Germain,et al.  TGF‐β receptor expression on human keratinocytes: A 150 kDa GPI‐anchored TGF‐β1 binding protein forms a heteromeric complex with type I and type II receptors , 1998, Journal of cellular biochemistry.

[247]  H. Lodish,et al.  Oligomeric Structure of Type I and Type II Transforming Growth Factor β Receptors: Homodimers Form in the ER and Persist at the Plasma Membrane , 1998, The Journal of cell biology.

[248]  Yigong Shi,et al.  The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF‐β receptors , 1998, The EMBO journal.

[249]  K. Irie,et al.  Role of TAK1 and TAB1 in BMP signaling in early Xenopus development , 1998, The EMBO journal.

[250]  C. Wernstedt,et al.  Phosphorylation of Ser465 and Ser467 in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor-β Signaling* , 1997, The Journal of Biological Chemistry.

[251]  Jeffrey L. Wrana,et al.  TβRI Phosphorylation of Smad2 on Ser465 and Ser467 Is Required for Smad2-Smad4 Complex Formation and Signaling* , 1997, The Journal of Biological Chemistry.

[252]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[253]  J. Massagué,et al.  Mechanism of TGFβ receptor inhibition by FKBP12 , 1997, The EMBO journal.

[254]  R. Derynck,et al.  A kinase subdomain of transforming growth factor‐β (TGF‐β) type I receptor determines the TGF‐β intracellular signaling specificity , 1997 .

[255]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[256]  R. Derynck,et al.  The Type II Transforming Growth Factor-β Receptor Autophosphorylates Not Only on Serine and Threonine but Also on Tyrosine Residues* , 1997, The Journal of Biological Chemistry.

[257]  H. Lodish,et al.  Positive and negative regulation of type II TGF‐β receptor signal transduction by autophosphorylation on multiple serine residues , 1997, The EMBO journal.

[258]  K. Miyazono,et al.  Phosphorylation of Ser165 in TGF‐beta type I receptor modulates TGF‐beta1‐induced cellular responses. , 1996 .

[259]  P. Donahoe,et al.  The Immunophilin FKBP12 Functions as a Common Inhibitor of the TGFβ Family Type I Receptors , 1996, Cell.

[260]  D. W. Johnson,et al.  Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.

[261]  J. Massagué,et al.  Complementation between kinase‐defective and activation‐defective TGF‐beta receptors reveals a novel form of receptor cooperativity essential for signaling. , 1996, The EMBO journal.

[262]  R. Derynck,et al.  Homomeric interactions between type II transforming growth factor-beta receptors. , 1994, The Journal of biological chemistry.

[263]  K. Miyazono,et al.  Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-beta. , 1994, The Journal of biological chemistry.

[264]  Jeffrey L. Wrana,et al.  Mechanism of activation of the TGF-β receptor , 1994, Nature.

[265]  H. Lodish,et al.  The types II and III transforming growth factor-beta receptors form homo-oligomers , 1994, The Journal of cell biology.

[266]  J. Massagué,et al.  Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites , 1994, The Journal of cell biology.

[267]  H. Lodish,et al.  The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. , 1993, The Journal of biological chemistry.

[268]  J. Massagué,et al.  Betaglycan presents ligand to the TGFβ signaling receptor , 1993, Cell.

[269]  J. Massagué,et al.  Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system , 1991, Cell.

[270]  Merlin C. Thomas,et al.  Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. , 2014, Kidney international.

[271]  J. Debus,et al.  Blockade of TGF-beta signaling by the TGF β R-I kinase Inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma , 2011 .

[272]  K. Mohammad,et al.  TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. , 2011, Cancer research.

[273]  K. Miyazono,et al.  Bone morphogenetic protein receptors and signal transduction. , 2010, Journal of biochemistry.

[274]  Xin-Hua Feng,et al.  Phospho-control of TGF-β superfamily signaling , 2009, Cell Research.

[275]  Mary E. Choi,et al.  Transforming Growth Factor-β (TGF-β1) Activates TAK1 via TAB1-mediated Autophosphorylation, Independent of TGF-β Receptor Kinase Activity in Mesangial Cells* , 2009, The Journal of Biological Chemistry.

[276]  R. Derynck,et al.  2 TGF-β and the TGF-β Family , 2008 .

[277]  In Ho Choi,et al.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva , 2006, Nature Genetics.

[278]  M. O’Connor,et al.  The TGF beta activated kinase TAK1 regulates vascular development in vivo. , 2006, Development.

[279]  K. Rai,et al.  Transforming growth factor-β (TGF-β)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-β receptor , 2004 .

[280]  M. Reiss,et al.  TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling. , 2003, The EMBO journal.

[281]  S. Erzurum,et al.  Pathobiology of pulmonary arterial hypertension. , 2002, The European respiratory journal.

[282]  Y. Henis,et al.  Transforming Growth Factor- Receptors Interact with AP2 by Direct Binding to 2 Subunit , 2002 .

[283]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[284]  D. Marchuk,et al.  Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. , 2000, Developmental biology.

[285]  Y. Henis,et al.  Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I/Type II receptor complex in live cells. , 1999, The Journal of biological chemistry.

[286]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[287]  R. Randall,et al.  Transforming Growth Factor (cid:2) -Induced Smad1/5 Phosphorylation in Epithelial Cells Is Mediated by Novel Receptor Complexes and Is Essential for Anchorage-Independent Growth (cid:1) † , 2008 .